GLP-1 weight loss injections are once-weekly prescription medications, semaglutide and tirzepatide, that mimic gut hormones to reduce appetite, slow gastric emptying, improve insulin response, and shift fat metabolism. In the STEP-1 trial, semaglutide produced 14.9 percent body weight loss; in SURMOUNT-1, tirzepatide produced 22.5 percent. DermaVue runs supervised GLP-1 protocols across 7 South Indian clinics.
The DermaVue Clinics medical team prescribes GLP-1 receptor agonists (semaglutide and tirzepatide) as part of a structured weight management protocol that includes weekly dose titration, monthly metabolic review, and a high-protein nutrition plan to preserve lean mass. GLP-1 therapy acts on four organ systems: brain appetite centres, stomach, pancreas, and liver. Across 7 physician-led DermaVue centres in Kerala and Tamil Nadu, the team has supported over 7,200 patient reviews with a 4.8 average star rating, focusing protocols on the visceral-fat-dominant South Asian phenotype.
The Problem Diets Can't Solve: Why Indians Gain Fat Differently
You eat clean. You exercise. Your weight is "normal." Yet your belly won't budge, your blood sugar is creeping up, and your doctor says everything looks fine on paper. Sound familiar?
The truth is, standard BMI charts were designed for European populations. They miss what researchers call the Asian Indian Phenotype. A genetic tendency to store dangerous visceral fat around internal organs, even at a "healthy" weight.
| Person | BMI | Body Fat % |
|---|---|---|
| Indian Doctor, Age 35 | 22.3 | 21.2% |
| European Doctor, Age 35 | 22.3 | 9.1% |
Same BMI. Completely different health risk. (Source: The Lancet)
This is the Asian Indian Phenotype: higher body fat percentage, more visceral fat deposition, greater insulin resistance, and elevated cardiovascular risk. All hidden behind a normal BMI number. It's the reason an Indian man with BMI 23 can have the metabolic profile of a European man with BMI 30.
Diet and exercise alone cannot selectively target visceral fat. Your body is hormonally programmed to hold onto it. That's where GLP-1 receptor agonist therapy changes the equation.
Are You Skinny Fat? Indian Risk Indicators
Indian BMI cutoffs are significantly lower than international standards. What's "normal" globally may already be overweight for you.
| Category | Indian BMI | International BMI |
|---|---|---|
| Normal | 18.0-22.9 | 18.5-24.9 |
| Overweight | 23.0-24.9 | 25.0-29.9 |
| Obese | ≥ 25.0 | ≥ 30.0 |
| Waist Circumference | At-Risk Threshold (Indian) |
|---|---|
| Men | > 85 cm (33.5 inches) |
| Women | > 75 cm (29.5 inches) |
You May Be Skinny Fat If:
How GLP-1 Injections Work for Belly Fat
GLP-1 (Glucagon-Like Peptide-1) is a hormone naturally produced in your gut after eating. It tells your brain you're full, slows stomach emptying, and regulates blood sugar. GLP-1 receptor agonist medications amplify this signal. And specifically target visceral fat around your organs.
Unlike diet pills that simply suppress appetite, GLP-1 medications work through four distinct mechanisms that address the root causes of stubborn belly fat in Indian patients.
Brain: Appetite Reset
Reduces hunger signals and stops food cravings. You feel satisfied with less food. Naturally, not through willpower.
Stomach: Delayed Emptying
Slows gastric emptying so food stays longer. You feel full for hours after a normal-sized meal.
Liver & Fat: Visceral Targeting
Targets visceral belly fat specifically. Reduces liver fat and improves lipid markers within weeks.
Pancreas: Insulin Fix
Improves insulin sensitivity and regulates blood sugar. Addresses the metabolic dysfunction driving fat storage.
GLP-1 Medications Available in India
Your dermatologist-led care team selects the right GLP-1 medication based on your metabolic profile and preferences.
GLP-1 Medications by Patient Profile
| Your Profile | Recommended GLP-1 | Format | Approx. Cost/Month |
|---|---|---|---|
| BMI 23-27 with belly fat | Semaglutide (Ozempic/Generic) | Weekly injection | From ₹5,660/mo |
| BMI >27 or high insulin resistance | Tirzepatide (Mounjaro) | Weekly injection | From ₹13,000/mo |
| Needle-phobic patients | Oral Semaglutide (Rybelsus) | Daily tablet | From ₹5,660/mo |
April 2026 Update: Generic semaglutide is now available in India following patent expiry, making GLP-1 therapy more accessible. Generic GLP-1 medications are entering the Indian market. Pricing will be updated as new options become available. Your DermaVue doctor will help you choose between branded and generic options based on your specific needs.
Clinical Results: STEP and SURMOUNT Trials
GLP-1 medications are backed by some of the largest clinical trials in obesity medicine history.
| Trial | Medication | Weight Loss | Duration | Key Finding |
|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4mg | 14.9% | 68 weeks | Significant visceral fat reduction |
| STEP 2 | Semaglutide (T2D patients) | 9.6% | 68 weeks | HbA1c improved by 1.6% |
| SURMOUNT-1 | Tirzepatide 15mg | 22.5% | 72 weeks | Highest weight loss in GLP-1 class |
| SURMOUNT-2 | Tirzepatide (T2D patients) | 14.7% | 72 weeks | Superior metabolic improvement |
These results represent averages from controlled trials [Wilding STEP 1, NEJM 2021] [Jastreboff SURMOUNT-1, NEJM 2022]. Beyond weight loss, the SELECT trial showed semaglutide reduces major adverse cardiovascular events by 20 percent in patients with obesity and established cardiovascular disease, even without diabetes [Lincoff SELECT, NEJM 2023]. The FLOW trial extended the case to the kidney, showing a 24 percent reduction in kidney disease progression in adults with type 2 diabetes and chronic kidney disease [Perkovic FLOW, NEJM 2024]. Indian patients with the thin-fat phenotype often experience disproportionately high improvements in waist circumference and metabolic markers even with modest overall weight loss, because GLP-1 preferentially targets the visceral fat that drives metabolic disease.
68 vs 72 weeks
STEP-1 (NEJM 2021) vs SURMOUNT-1 (NEJM 2022) head-to-head body weight loss.
Body fat percentage
Same BMI, 2x body fat. Why diet alone fails for Indian patients.
68 vs 72 weeks in T2D
STEP-2 also showed 1.6% HbA1c improvement at 68 weeks.
Why Belly Fat Needs Medical Treatment (Not Just Diet)
If willpower alone could fix visceral fat, you wouldn't be reading this. Here's why conventional approaches fail. And what actually works.
| Approach | What It Does | Why It Fails for Visceral Fat |
|---|---|---|
| Calorie Counting | Cuts total calorie intake | Doesn't fix hormonal fat storage signals |
| Gym / Exercise | Burns calories, builds muscle | Cannot selectively target internal organ fat |
| Intermittent Fasting | Restricts eating windows | Causes muscle loss and rebound hunger |
| Ayurveda / Herbs | Various traditional claims | No clinical evidence for visceral fat reduction |
What GLP-1 Does That Nothing Else Can
GLP-1 receptor agonists work at the hormonal level to reprogram your body's fat storage signals. Clinical evidence shows:
- ✓ 14 to 22% total body weight loss in clinical trials
- ✓ Preferential reduction of visceral (belly) fat over subcutaneous fat
- ✓ Improved insulin sensitivity within 4 to 8 weeks
- ✓ Reduced liver fat (NAFLD improvement) in 60 to 70% of patients
- ✓ Sustained appetite regulation. Not willpower, but biology
Who Qualifies for GLP-1 Therapy?
GLP-1 therapy is a prescription medication. Your DermaVue doctor will assess your eligibility based on Indian ICMR guidelines.
You May Qualify If:
- ✓ BMI ≥ 23 (Indian cutoff) with central obesity
- ✓ Waist > 85 cm (men) or > 75 cm (women)
- ✓ Normal BMI but high body fat percentage (skinny fat)
- ✓ Pre-diabetes or insulin resistance
- ✓ Metabolic syndrome (elevated triglycerides, low HDL)
- ✓ Type 2 diabetes with overweight
- ✓ Failed diet and exercise attempts for belly fat
Contraindications (Not Suitable If):
- ✗ Family history of medullary thyroid carcinoma (MTC)
- ✗ Multiple Endocrine Neoplasia type 2 (MEN-2)
- ✗ History of pancreatitis
- ✗ Pregnancy, planning pregnancy, or breastfeeding
- ✗ Severe kidney impairment (eGFR < 30)
The SuperHuman Program Includes
Not all GLP-1 programs are equal. DermaVue's SuperHuman Program is the only dermatologist-led weight loss program in South India with built-in skin protection.
Board-Certified Dermatologists (IADVL)
Your skin changes during weight loss. Our dermatologists monitor and protect your skin throughout the GLP-1 program. Preventing sagging, stretch marks, and dullness.
US-Trained Medical Director
Dr. Rejeesh Menon brings international training and evidence-based protocols. Every treatment plan is reviewed and approved by our medical director.
Dietitian-Led Nutrition Program
Weekly consultations with certified dietitians. Protein optimization, micronutrient planning, and meal strategies designed specifically for GLP-1 patients.
Face-Saver Protocol
The only GLP-1 program in Kerala with built-in "Ozempic Face" prevention. Targeted facial treatments, collagen support, and volume preservation strategies from day one.
Body Composition Tracking
Monthly bioelectrical impedance analysis tracks visceral fat, muscle mass, and body water. We measure what matters. Not just the number on the scale.
7 Locations Across South India
Thiruvananthapuram, Kollam, Thiruvalla, Kottayam, Kochi-Aluva, Thrissur, Coimbatore. Convenient access across Kerala and Tamil Nadu with consistent protocols at every location.
Side Effects & How We Manage Them
GLP-1 side effects are real but manageable. DermaVue's gradual dose titration protocol minimizes discomfort.
Nausea (44%)
Most common in weeks 1 to 4 during dose titration. We manage this with slow dose escalation, dietary timing strategies, and anti-nausea support when needed. Typically resolves by week 6 to 8.
GI Symptoms (24%)
Constipation, diarrhea, or bloating may occur early. Our dietitians adjust fibre intake and hydration protocols. Symptoms are dose-dependent and improve with gradual titration.
Muscle Loss Prevention
Rapid weight loss can cause muscle wasting. The SuperHuman Program includes protein optimization (1.2 to 1.6g/kg/day), resistance training guidance, and regular body composition checks to preserve lean mass.
Weekly check-ins during the first month, then fortnightly reviews. Your DermaVue care team is available via WhatsApp between appointments for any concerns.
Generic GLP-1 Update. March 2026
Generic semaglutide entered the Indian market in March 2026. Branded Ozempic at 0.5 mg weekly previously ran around Rs 8,100 per month. Indian generics from Natco, Alkem, and Dr. Reddy's now sit between Rs 1,290 and Rs 4,200 at the same dose. The molecule and safety profile are identical. Physician supervision is still required because GLP-1 therapy carries real contraindications. Cheaper does not mean safer to self-prescribe.
Medically reviewed by Dr. Rejeesh Menon, MD · Medical Director, DermaVue Clinics · Last reviewed 5 April 2026
GLP-1 Injections FAQ
Everything you need to know about GLP-1 therapy for belly fat at DermaVue.
What & Safety
What exactly is GLP-1 therapy?
GLP-1 receptor agonist therapy uses medications that mimic the natural GLP-1 hormone to reduce appetite, slow digestion, and target visceral belly fat. Available as weekly injections (Ozempic, Mounjaro) or daily oral tablets (Rybelsus). These medications were originally developed for type 2 diabetes and are now approved for weight management.
Is GLP-1 safe for Indians with BMI 23 to 27?
Yes, with proper medical screening. Indian guidelines define overweight as BMI ≥ 23 (compared to 25 internationally). GLP-1 is particularly effective for the thin-fat phenotype with central obesity at normal Western BMI cutoffs. Your DermaVue doctor will assess your metabolic profile, waist circumference, and blood markers before prescribing.
What are the side effects of GLP-1 injections?
Common side effects include nausea (44%), vomiting (24%), and constipation (24%). These typically resolve within 4 to 8 weeks as your body adjusts. DermaVue's gradual dose titration protocol minimizes side effects. We start low and increase slowly, with weekly check-ins during the first month.
Results & Timeline
How much weight can I expect to lose?
Clinical trials show 14 to 22% total body weight loss over 12 to 18 months. Individual results depend on medication choice, adherence, diet, and exercise. Indian patients with the skinny-fat phenotype often see dramatic improvements in waist circumference and metabolic markers even with modest overall weight loss.
How long does GLP-1 treatment take to show results?
Most patients notice reduced appetite within the first week. Visible weight changes typically occur by weeks 4 to 6. Significant results (10 to 20% body weight reduction) are seen by months 3 to 6 depending on the medication and individual response.
Special Populations
Can I take GLP-1 if I have diabetes?
Yes, type 2 diabetes is actually a primary indication for GLP-1 medications. They improve both weight and blood sugar control simultaneously. Your doctor will adjust your existing diabetes medications accordingly to prevent hypoglycaemia. GLP-1 is not recommended for type 1 diabetes.
Will I regain weight after stopping GLP-1?
Some weight regain is possible, which is why the SuperHuman Program focuses on building sustainable habits alongside medication. Protein optimization, resistance training, and behavioral changes help maintain results long-term. Many patients transition to a lower maintenance dose rather than stopping completely.
Cost
How much does GLP-1 treatment cost at DermaVue?
GLP-1 therapy at DermaVue starts at ₹5,660 per month for semaglutide and ₹13,000 per month for Mounjaro (tirzepatide). The SuperHuman Program includes doctor consultations, dietitian support, body composition tracking, and the Face-Saver Protocol. EMI options are available at all 7 clinic locations. Generic GLP-1 medications are entering the Indian market. Pricing will be updated as new options become available.
Visit Any of Our 7 Clinics
Or book a teleconsultation from anywhere in India
Ready to Lose the Belly Fat That Diets Can't Touch?
Book a doctor assessment to check your eligibility for GLP-1 therapy. Available at all 7 DermaVue clinics across Kerala and Tamil Nadu, or via teleconsultation.